Connect with us


PharmEasy appoints Aamir Khan as its brand ambassador




Mumbai, 1st April 2022: PharmEasy, a consumer healthcare ‘super app’ has launched its latest campaign starring the Bollywood superstar Aamir Khan as its brand ambassador! The PharmEasy brand is managed by API Holdings Limited.

The PharmEasy brand is committed to providing a seamless healthcare experience. This association will help towards building the brand and creating consumer awareness for healthcare in India. Aamir will be seen endorsing the PharmEasy brand via various mediums. TVCs featuring Aamir Khan will also be a part of the IPL campaign 2022. As a face of the brand, he will also accentuate how medicines, diagnostic tests and healthcare products are conveniently available at customers’ fingertips.

#GharBaitheBaitheTakeItEasy campaign brings Aamir Khan as the new brand ambassador of the healthcare brand PharmEasy and introduces him in a set of quirky, disruptive and ‘mad-humour’ genre TVCs. This campaign is conceptualised by FCB India. Aamir plays a triple role of the PharmEasy delivery person who pops up in the oddest places and in the craziest manner to tell customers about all the offerings from the PharmEasy brand and how all that people need to do now is ‘Take It Easy’ (at least when it comes to their healthcare needs).

With this association, the aim is to make the PharmEasy brand a household name for every Indian when it comes to healthcare. Collaborating with Aamir Khan will further strengthen the brand’s belief in making healthcare accessible to every nook and corner of the country.

Talking about the collaboration Gaurav Verma, CMO at API Holdings said, “Collaborating with someone as versatile as Aamir Khan fills us with immense joy. We are absolutely thrilled to have him on board as the face of the brand PharmEasy. He truly knows how to engage with the audience. With this association, we aim to reach more people while making affordable healthcare accessible to everyone. We are looking forward to a great collaboration with him this year and widening our reach through offerings and such campaigns.”

Speaking on the collaboration, Aamir Khan said, “It is indeed a pleasure to work together with the PharmEasy brand, to help provide economical healthcare at each person’s doorstep. I feel that in today’s times, PharmEasy is providing an essential service, in a sector that is itself a fundamental requirement for all of us, and I look forward to this association.”

Aamir Khan’s persona and ability to connect with people, and his commitment towards healthcare will deepen the company’s mission to ensure good health for one and all.




About PharmEasy : PharmEasy is a consumer healthcare ‘super app’ that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs. API Holdings Limited manages the PharmEasy brand.

About API : API Group is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021) according to the RedSeer Report which operates an integrated, end-to-end business solving the healthcare needs of consumers through technology and fulfilment capabilities.

“API Holdings Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at as well as on the websites of the book running lead managers, Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited and JM Financial Limited at,,, and respectively, and the websites of the stock exchange(s) at and, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the RHP, when available. Potential investors should not rely on the DRHP for any investment decision.”